

**Table 7.** Comparison of the clinical characteristics between the groups with and without ACS in HFpEF patients

	<b>Without ACS group (n = 400)</b>	<b>With ACS group (n = 97)</b>	<b>P value</b>
The modified H <sub>2</sub> FPEF score	5.23±2.13	6.49±2.11	<0.001
Age (years)	68.63±10.74	70.80±9.10	0.066
Female (%)	229 (57.3)	59 (60.8)	0.522
BMI (kg/m <sup>2</sup> )	27.71±3.65	27.16±2.92	0.495
SBP (mm Hg)	134.72±20.72	137.71±20.93	0.204
DBP (mm Hg)	78.71±13.10	80.33±12.89	0.273
Heart rate	83.52±26.78	80.08±22.16	0.243
Smoking (%)	55 (13.8)	20 (20.6)	0.090
Hypertension (%)	281 (70.3)	77 (79.4)	0.072
Diabetes (%)	98 (24.5)	25 (25.8)	0.794
Atrial fibrillation (%)	207 (51.8)	64 (66.0)	0.012
Abnormal of thyroid function (%)	113 (28.3)	24 (24.7)	0.471
Ischemic heart disease (%)	199 (49.8)	59 (60.8)	0.050
Previous hospitalization for HF (%)	88 (22.0)	42 (43.3)	<0.001
NYHA			
I (%)	1 (0.3)	-	-
II (%)	266 (66.5)	56 (57.7)	<0.05
III (%)	111 (27.8)	36 (37.1)	<0.05
IV (%)	22 (5.5)	5 (5.2)	>0.05
Blood test			
BNP (pmol/L)	382.83±337.82	398.59±331.96	0.734
Cre (μmol/L)	77.06±23.36	76.96±20.44	0.970
eGFR (mL/min/1.73 m <sup>2</sup> )	78.18±19.26	77.03±18.44	0.596
UA (μmol/L)	332.72±105.77	335.73±91.77	0.550

ALT (U/L)	20.92±15.78	23.61±27.66	0.197
AST (U/L)	22.17±12.42	22.42±16.10	0.867
Hemoglobin (g/L)	130.78±19.85	131.63±18.23	0.701
K <sup>+</sup> (mmol/L)	3.99±0.47	4.03±0.46	0.426
Na <sup>+</sup> (mmol/L)	142.46±3.24	142.67±2.97	0.570
Serum glucose (mmol/L)	5.48±2.13	5.38±1.69	0.670
HbA1c (%)	6.27±1.23	6.17±0.86	0.453
TC (mmol/L)	3.99±0.97	3.79±0.87	0.060
TG (mmol/L)	1.23±0.76	1.30±0.52	0.689
LDL-C (mmol/L)	2.47±0.84	2.34±0.78	0.173
HDL-C (mmol/L)	1.16±0.28	1.08±0.26	0.008
Echocardiography			
e' (cm/s)	5.53±1.86	5.27±1.43	0.187
LVMI (g/m)	112.24±27.46	113.36±31.47	0.727
LVED (mm)	46.21±4.62	46.08±4.12	0.807
LAD (mm)	37.85±5.21	37.91±4.88	0.925
RVD (mm)	22.19±4.94	22.27±5.11	0.890
IVST (mm)	10.11±1.28	10.34±1.41	0.121
LVPW (mm)	10.06±1.26	10.28±1.43	0.136
RAD (mm)	47.62±6.44	47.71±7.20	0.900
LVEF (%)	62.04±4.81	61.84±5.22	0.716
E/e'	15.35±6.97	16.43±8.17	0.187
PAP (mmHg)	33.09±8.96	33.96±9.13	0.400
Drug therapy			
Beta-blocker (%)	228 (57.0)	70 (72.2)	0.006
ACEI/ARB (%)	146 (36.5)	27 (27.8)	0.108
Spirolactone (%)	167 (41.8)	45 (46.4)	0.407
Loop diuretic (%)	289 (72.3)	79 (81.4)	0.064
CCB (%)	116 (29.0)	44 (45.4)	0.002
Digoxin (%)	20 (5.0)	1 (1.0)	0.081

Antiplatelet drug (%)	219 (54.8)	67 (69.1)	0.010
Anticoagulant drug (%)	324 (81.0)	86(88.7)	0.075
HMG-CoA reductase inhibitor (%)	288 (72.0)	84(86.6)	0.003
Intervention therapy			
PCI (%)	54 (13.5)	25 (25.8)	0.003
Radiofrequency ablation (%)	120 (30.0)	21 (21.6)	0.102
ICD (%)	67 (16.8)	5 (5.2)	0.004
CABG (%)	4 (1.0)	3 (3.1)	0.117

HFpEF: heart failure with preserved ejection fraction; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; NYHA, New York Heart Association; Cre, creatinine; eGFR, estimated glomerular filtration rate; UA, uric acid; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TC, cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; LVMI, *Left ventricular mass index*; LVED, Left ventricular end diastolic; LAD, left atrial diameter; RAD, right atrial diameter; RVD, right ventricle diameter; IVST, interventricular septal thickness; LVPW, left ventricular posterior wall thickness; LVEF, left ventricular ejection fraction; E/e', mitral Doppler early velocity/mitral annular early velocity; PAP, pulmonary artery systolic pressure; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blockers; HMG-CoA,  $\beta$ -Hydroxy  $\beta$ -methylglutaryl-CoA; PCI, percutaneous coronary intervention. ICD, implantable cardioverter defibrillators. CABG, coronary artery bypass graft.